| Filed On | Filing |
|---|---|
| 13 Nov 2026 | SCHEDULE 13G/A |
| 12 Nov 2026 |
Form 4: Feuchtwang Ilan, Chief Legal Officer, Secretary
Granted 25,745 Restricted Stock Units |
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
FREMONT, Calif., November 4, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended Septemb... |
| 03 Nov 2026 | SCHEDULE 13G/A |
| 29 Sep 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. |
| 02 Sep 2026 | 144 |
| 24 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
FREMONT, Calif., August 21, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences,” “Cytek,” or the “Company”) (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that a jury in the United States Dist... |
| 20 Aug 2026 |
Form 4: Jiang Wenbin, Director
Received 120,095 shares by exercise or conversion · Gave up 36,269 shares to cover exercise price or tax ($169K) |
| 20 Aug 2026 |
Form 4: McCombe William D., Chief Financial Officer
Received 35,420 shares by exercise or conversion · Gave up 11,904 shares to cover exercise price or tax ($55.6K) |
| 20 Aug 2026 |
Form 4: Muir Glenn P, Director
Received 3,086 shares by exercise or conversion |
| 20 Aug 2026 |
Form 4: Holder Michael, Director
Received 2,181 shares by exercise or conversion |
| 20 Aug 2026 |
Form 4: Chin Richard, Director
Received 6,107 shares by exercise or conversion |
| 20 Aug 2026 |
Form 4: Yan Ming, Director
Received 33,270 shares by exercise or conversion · Gave up 8,088 shares to cover exercise price or tax ($37.8K) |
| 12 Aug 2026 |
Form 4: Feuchtwang Ilan, Chief Legal Officer, Secretary
Granted 241,416 Restricted Stock Units · Granted 127,118 Employee Stock Option (right to buy) |
| 06 Aug 2026 | SCHEDULE 13G/A |
| 05 Aug 2026 | 10-Q |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
FREMONT, Calif., August 5, 2026 (GLOBE NEWSWIRE) – Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30,... |
| 04 Aug 2026 | SCHEDULE 13G |
| 15 Jul 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Loading...